Drugs / dasatinib anhydrous
dasatinib anhydrous
also known as
Dasatinib · SPRYCEL · BMS-354825 · XS004 · BMS-354825 HYDRATE · BMS-354825-03 · BMS-354835 · DAS · +11 more
Small molecule targets ABL1, EPHA2, ERBB4, FGFR3, FYN, HCK, KIT, LCK, LYN, PDGFRA, PDGFRB, SRC, YES1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 10 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | PHYRAGO | — | 2025-08-01 | fda.gov ↗ |
| Label expansions (7) | US (FDA) | SPRYCEL | — | 2007-11-08 – 2018-12-21 | fda.gov ↗ |
| Approved | EU (EMA) | Sprycel | — | 2006-11-20 | europa.eu ↗ |
| Approved | US (FDA) | SPRYCEL | — | 2006-06-28 | fda.gov ↗ |
Trials 285 · started per year
today
US approved 2006
EU approved 2006
2
4
11
14
35
21
31
8
16
16
10
10
11
18
9
6
3
11
9
10
8
8
8
4
2004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
Also used as a comparator or background therapy in 57 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 112 trials | ||||||
| Phase 1 | NCT04872790 Background | Sep 2022 → Dec 2027 expected | B-cell acute lymphoblastic leukemia, B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), mixed phenotype acute leukemia | OHSU Knight Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04580121 Background | Nov 2020 → Aug 2023 | acute myeloid leukemia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT03595917 Background | Jul 2018 → Nov 2026 expected | B-cell acute lymphoblastic leukemia, B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), blast phase chronic myelogenous leukemia, BCR-ABL1 positive | Marlise Luskin, MD | Recruiting | No outcome recorded |
| Phase 1 | NCT03515200 Background | Apr 2018 → Jul 2020 | acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Terminated | No outcome recorded |
| Phase 1 | NCT02494882 Background | Jun 2015 → Jun 2027 expected | acute lymphoblastic leukemia | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02129166 Comparator | Sep → Oct 2014 | — | University of Florida | Withdrawn | No outcome recorded |
| Phase 1 | NCT02081378 Background | Apr 2014 → Jun 2021 | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), chronic myeloid leukemia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02047149 Background | Jan 2014 → Jun 2016 | chronic myeloid leukemia | University of Massachusetts, Worcester | Terminated | No outcome recorded |
| Phase 1 | NCT01751425 Background | Jul 2013 → Sep 2019 | Philadelphia-positive myelogenous leukemia, chronic myeloid leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT00500006 Background | Oct → Nov 2007 | chronic myeloid leukemia, precursor lymphoblastic lymphoma/leukemia | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1 | NCT00598091 Comparator | Apr 2007 → Jun 2010 | pancreatic adenocarcinoma | Duke University | Terminated | No outcome recorded |
| Phase 1 | NCT00162214 Comparator | Aug 2005 → Mar 2007 | neoplasm | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 1/28 trials | ||||||
| Phase 1/2 | NCT05506488 Comparator | Jul 2023 → Feb 2026 | fibrotic liver disease, metabolic dysfunction-associated steatohepatitis | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| Phase 1/2 | NCT05192889 Background | Aug 2022 → Jun 2024 overdue | acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04006847 Background | Sep 2020 → May 2021 | chronic myeloid leukemia | Milton S. Hershey Medical Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT02923986 Background | Sep 2017 → May 2020 | Philadelphia-positive myelogenous leukemia, acute myeloid leukemia, myelodysplastic syndrome | Bio-Path Holdings, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00903006 Comparator | Nov 2009 → May 2013 | breast cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT00948389 Comparator | Oct 2009 → May 2011 | glioblastoma | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 1/2 | NCT00949988 Comparator | May 2009 → Apr 2012 | B-cell chronic lymphocytic leukemia | University of California, San Diego | Terminated | No outcome recorded |
| Phase 1/2 | NCT00439270 Comparator | Jul 2007 → Feb 2012 | metastatic prostate carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 226 trials | ||||||
| Phase 2 | NCT06773936 Background | May 2026 → May 2029 expected | B-cell acute lymphoblastic leukemia, B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) | SWOG Cancer Research Network | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT07493408 Background | Mar 2026 → Dec 2035 expected | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), blast phase chronic myelogenous leukemia, BCR-ABL1 positive, disease related to hematopoietic stem cell transplant | The University of Hong Kong | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06533748 Background | Jan 2025 → May 2028 expected | lymphoblastic lymphoma, precursor B-cell acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04733534 Comparator | Jun 2022 → Dec 2026 expected | childhood malignant neoplasm | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04838041 Background | Nov 2021 → Jun 2028 expected | chronic myeloid leukemia | Medical College of Wisconsin | Recruiting | No outcome recorded |
| Phase 2 | NCT04925648 Comparator | Oct 2021 → Sep 2025 | metastatic prostate carcinoma | St Vincent's Hospital, Sydney | Completed | No outcome recorded |
| Phase 2 | NCT04626024 Background | Dec 2020 → Nov 2028 expected | chronic myeloid leukemia | Baylor College of Medicine | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04329325 Background | Mar 2020 → Mar 2027 expected | acute lymphoblastic leukemia | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04126681 Comparator | Oct 2019 → Aug 2024 | chronic myeloid leukemia | Ascentage Pharma Group Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03906292 Background | Aug 2019 → Dec 2027 expected | chronic myeloid leukemia | University of Jena | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03516279 Background | Jun 2019 → Aug 2028 expected | chronic myeloid leukemia | ECOG-ACRIN Cancer Research Group | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03654768 Background | Oct 2018 → Jul 2024 overdue | chronic myeloid leukemia | SWOG Cancer Research Network | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02848131 Comparator | Jul 2016 → Apr 2027 expected | chronic kidney disease | Mayo Clinic | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT02559778 Comparator | Sep 2015 → Sep 2030 expected | neuroblastoma | Giselle Sholler | Recruiting | No outcome recorded |
| Phase 2 | NCT02297139 Background | Jul 2015 → May 2022 | cancer of unknown primary site | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT01990196 Comparator | Sep 2014 → Sep 2024 overdue | prostate cancer | Jonsson Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01703910 Comparator | Nov 2012 | colon adenocarcinoma, metastatic neoplasm, rectum adenocarcinoma | Spanish National Cancer Research Centre | Completed | No outcome recorded |
| Phase 2 | NCT01887561 Comparator | Nov → Dec 2012 | chronic myeloid leukemia | Kanto CML Study Group | Unknown | No outcome recorded |
| Phase 2 | NCT01593254 Comparator | Sep 2012 → Nov 2017 | chronic myeloid leukemia | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT01395017 Comparator | Jun 2011 → Oct 2013 | malignant pancreatic neoplasm | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01092728 Comparator | Mar 2011 → Aug 2014 | melanoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT00918385 Comparator | May 2009 → Feb 2012 | prostate cancer | Duke University | Terminated | No outcome recorded |
| Phase 2 | NCT00767520 Comparator | Feb 2009 → Mar 2011 | breast cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT00696072 Comparator | Aug 2008 → Jun 2014 | Her2-receptor negative breast cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT00320190 Comparator | Aug 2006 → Jan 2010 | chronic myeloid leukemia | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 2 | NCT00036738 Background | Jul 2001 → Jul 2014 | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), adult acute lymphoblastic leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, childhood acute lymphoblastic leukemia | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03117751 Background | Mar 2017 → Sep 2026 expected | lymphoblastic leukemia, acute, with lymphomatous features | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT04971226 Comparator | Oct 2021 → Nov 2023 overdue | chronic myeloid leukemia | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03020030 Background | Mar 2017 → Nov 2026 expected | childhood acute lymphoblastic leukemia | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00744497 Comparator | Oct 2008 → Aug 2012 | prostate neoplasm | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00549848 Background | Oct 2007 → Sep 2020 | acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00362466 Comparator | Apr 2007 → Jun 2008 | leukemia | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07046182 Background | Oct 2023 → May 2028 expected | angioimmunoblastic T-cell lymphoma | Zhengzhou University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04933526 Comparator | Jul 2021 → Apr 2023 | chronic myeloid leukemia | Shenzhen Second People's Hospital | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05751733 Comparator | Feb 2023 → Jan 2026 overdue | gastrointestinal stromal tumor | Xiangya Hospital of Central South University | Recruiting | No outcome recorded |
| — | NCT05026229 Background | Sep 2021 → Jun 2023 | adult acute lymphoblastic leukemia | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT00454753 Background | — | — | Bristol-Myers Squibb | No longer available | No outcome recorded |
Press releases naming this drug 11 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-02-11 | Bristol-Myers Squibb | European Commission Approves Bristol-Myers Squibb’s Sprycel (dasatinib) in Combination with Chemotherapy for Treatment of Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia bms.com ↗ |
| 2015-08-13 | Otsuka Pharmaceutical Development & Commercialization, Inc. | FDA Approves U.S. Product Labeling Update for Sprycel® (dasatinib) to Include Five-Year First-Line and Seven-Year Second-Line Efficacy and Safety Data in Chronic Myeloid Leukemia in Chronic Phase otsuka-us.com ↗ |
| 2013-06-20 | Otsuka Pharmaceutical Development & Commercialization, Inc. | FDA Approves U.S. Product Labeling Update for SPRYCEL® (dasatinib) to Include Three-Year First-Line and Five-Year Second-Line Efficacy and Safety Data in Chronic Myeloid Leukemia in Chronic Phase otsuka-us.com ↗ |
| 2011-06-16 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Anti-cancer agent "Sprycel® 20mg Tablets and Sprycel® 50mg Tablets (dasatinib)" approved as the first-line treatment of chronic myeloid leukemia-A new treatment option for newly-diagnosed CML patients- otsuka.co.jp ↗ |
| 2010-12-21 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Starting co-promotion of the anti-cancer agent “SPRYCEL Tablet 20mg and SPRYCEL Tablet 50mg” (dasatinib) in Japan ®® otsuka.co.jp ↗ |
| 2010-12-17 | Otsuka Pharmaceutical Development & Commercialization, Inc. | The results of a subset analysis of Japanese patients from the DASISION trial comparing SPRYCEL (dasatinib) with imatinib in the treatment of newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia.® otsuka.co.jp ↗ |
| 2010-12-07 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Follow-Up Results from Study Comparing SPRYCEL (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Demonstrate Improved Response Rates Consistent with 12 Month Data®*1 otsuka.co.jp ↗ |
| 2010-11-01 | Otsuka Pharmaceutical Development & Commercialization, Inc. | FDA Approves SPRYCEL (dasatinib) as Treatment for Adult Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia in Chronic Phase® otsuka.co.jp ↗ |
| 2010-07-12 | Otsuka Pharmaceutical Development & Commercialization, Inc. | SPRYCEL (dasatinib) Receives FDA Priority Review for the Treatment of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase® otsuka.co.jp ↗ |
| 2010-06-09 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Four-Year Follow-Up Data for SPRYCEL (dasatinib) Demonstrate 82 Percent Overall Survival in Patients with Chronic Myeloid Leukemia Who Failed Gleevec®®* otsuka.co.jp ↗ |
| 2010-06-08 | Otsuka Pharmaceutical Development & Commercialization, Inc. | SPRYCEL (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevecin Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase®®* otsuka.co.jp ↗ |
Evidence & citations 27 cited values
Every value below carries the sentence it was read from. 348 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dasatinib anhydrous | “estimate the safety and tolerability of dasatinib anhydrous (dasatinib) in the setting of COVID-19 infection.” NCT04830735 ↗ |
| Known as | BMS-354825 | “Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib” NCT00101660 ↗6“Long-Term Safety and Efficacy of Dasatinib (BMS-354825) in Subjects Who Experienced Clinical Benefit on Protocol CA 180-002” NCT00345826 ↗ “Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase” NCT00324077 ↗ “Dasatinib = BMS-354825, Sprycel” NCT00652574 ↗ “Drug: Dasatinib (BMS-354825)” NCT00255346 ↗ “Dasatinib (BMS-354825)” NCT00388427 ↗ “Dasatinib (BMS-354825)” NCT00364286 ↗ |
| Known as | BMS-354825 HYDRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1421 ↗ |
| Known as | BMS-354825-03 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1421 ↗ |
| Known as | BMS-354835 | “Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia” NCT00103844 ↗ |
| Known as | DAS | “Dasatinib (DAS) and interferon-α have antileukemic and immunostimulatory effects and induce deep responses in chronic myeloid leukemia (CML).” PMID 27133821 ↗ May 2016 |
| Known as | Dasatinib | “Per patient, the inhibitory potency of sunitinib, dasatinib, erlotinib, sorafenib, everolimus, and lapatinib was determined in tumor lysates from fresh biopsies using a...” PMID 30018133 ↗ Jul 2018342“Low dose tyrosine kinase inhibitor (lowTKI) (dasatinib 50 mg daily or imatinib 300 mg daily or nilotinib 300 mg daily) at investigators discretion” NCT05143840 ↗ “Imatinib was given at a dose of 400mg/d or 600mg/d, dasatinib at a dose of 100mg/d or 140mg/d, and nilotinib at a dose of 400mg twice daily.” NCT01883219 ↗ “subjects with molecular typing of ABL1/ABL2/PDGFRB fusion were to receive chemotherapy combined with dasatinib 100mg orally once a day” NCT07203352 ↗ “subjects will take 140 mg of dasatinib along with 58 mg to 174 mg (based on body weight) bio-quercetin and 44.5 mg bio-fisetin” NCT04994561 ↗ “a drug called Asciminib (having different way of action), used either by itself or with another drug called Dasatinib” NCT07538401 ↗ “Imatinib was initiated at a dose of 200mg/d, dasatinib at a dose of 50mg/d, and ponatinib at a dose of 30mg/d.” NCT03624530 ↗ “The BCR-ABL TKIs that will be used include imatinib, dasatinib, nilotinib or bosutinib.” NCT03610971 ↗ “Dasatinib is a potent BCR-ABL inhibitor with proven efficacy in adults” PMID 23715577 ↗ May 2013 “Hydroxychloroquine, Metformin, Sirolimus, Dasatinib” NCT05036226 ↗ “Asciminib, Dasatinib, Prednisone, and Methotrexate” NCT06773936 ↗ “Dabrafenib Dasatinib Daunorubicin HCl” NCT02551718 ↗ “Dactinomycin, Dasatinib, Daunorubicin” NCT02788201 ↗ “Drug: Dasatinib” NCT06645886 ↗ “Drug: Dasatinib” NCT00529763 ↗ “Drug: Dasatinib” NCT01445509 ↗ “Dasatinib” NCT04006847 ↗ “Dasatinib” NCT01703910 ↗ “Dasatinib” NCT02142036 ↗ |
| Known as | Dasatinib accord | ChEMBL registry synonym — accepted as the source's own label CHEMBL1421 ↗ |
| Known as | Dasatinib accord healthcare | ChEMBL registry synonym — accepted as the source's own label CHEMBL1421 ↗ |
| Known as | Dasatinib accordpharma | ChEMBL registry synonym — accepted as the source's own label CHEMBL1421 ↗ |
| Known as | Dasatinib hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1421 ↗ |
| Known as | Dasatinib monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1421 ↗ |
| Known as | Dasatinib/BMS-354825 | “Dasatinib/BMS-354825” NCT01392703 ↗ |
| Known as | NSC #732517 | “A Phase II Study of Dasatinib (NSC #732517) in Patients With Previously Treated Malignant Mesothelioma” NCT00509041 ↗ |
| Known as | NSC-759877 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1421 ↗ |
| Known as | SPRYCEL | “Comparative Bioavailability of XS004 (Dasatinib) Formulation G and SPRYCEL® (Dasatinib) in Healthy, Adult Subjects Under Fasting Conditions” NCT05439408 ↗12“SPRYCEL® (dasatinib) 100 mg Film-Coated Tablets in combination with Omeprazole Delayed-Release Capsules USP, 40 mg” NCT06145217 ↗ “Dasatinib (D) is given as (1) 100mg capsule daily for 2 consecutive days (Sprycel®, Bristol Myers Squibb).” NCT04685590 ↗ “A Phase II Study of Dasatinib (Sprycel®) (NSC #732517) as Primary Therapy” NCT01256398 ↗ “Subjects will be evaluated for the efficacy and safety of dasatinib (Sprycel).” NCT01802450 ↗ “Dasatinib (SPRYCEL®) vs. Dasatinib Plus Smoothened Antagonist (BMS-833923)” NCT01357655 ↗ “Sprycel® (dasatinib): 20 mg and 50 mg tablets.” NCT02233049 ↗ “It is sold under the name of Sprycel.” NCT00817531 ↗ “Dasatinib = BMS-354825, Sprycel” NCT00652574 ↗ “Dasatinib(Sprycel) arm” NCT06257394 ↗ “dasatinib (SPRYCEL®)” NCT02890784 ↗ “dasatinib (SPRYCEL)” NCT00892190 ↗ “Dasatinib (Sprycel)” NCT00895297 ↗ |
| Known as | Sprycel (Dasatinib) | “Sprycel (Dasatinib)” NCT00597038 ↗ |
| Known as | Vysentri | ChEMBL registry synonym — accepted as the source's own label CHEMBL1421 ↗ |
| Known as | XS004 | “Comparative Bioavailability of XS004 (Dasatinib) Formulation G and SPRYCEL® (Dasatinib) in Healthy, Adult Subjects Under Fasting Conditions” NCT05439408 ↗1“XS004 (Dasatinib) Tablets” NCT05433896 ↗ |
| Known as | 依尼舒 | “自诱导化疗第8天开始口服达沙替尼（商品名依尼舒，正大天晴药业集团股份有限公司产品）100 mg/d，持续应用至整体治疗结束。” PMID 33858040 ↗ Feb 2021 |
| Action | Inhibit | “Platelet-derived growth factor receptor beta inhibitor” CHEMBL1421 ↗1“dasatinib, a BCR-ABL inhibitor” PMID 16775234 ↗ Jun 2006 |
| Modality | Small molecule | “Although second generation TKIs like dasatinib proved more efficient in achieving molecular remission compared to first generation TKI imatinib” PMID 30120281 ↗ Aug 2018 |
| Route | Oral | “dasatinib PO” NCT00036738 ↗ |
| Target | EPHA2 | “activation or overexpression of ≥ 2 putative dasatinib targets in GBM (ie, SRC, c-KIT, EPHA2, and PDGFR).” PMID 25758746 ↗ Mar 2015 |
| Target | KIT | “activation or overexpression of ≥ 2 putative dasatinib targets in GBM (ie, SRC, c-KIT, EPHA2, and PDGFR).” PMID 25758746 ↗ Mar 2015 |
| Target | PDGFRB | “Platelet-derived growth factor receptor beta inhibitor” CHEMBL1421 ↗ |
| Target | SRC | “activation or overexpression of ≥ 2 putative dasatinib targets in GBM (ie, SRC, c-KIT, EPHA2, and PDGFR).” PMID 25758746 ↗ Mar 2015 |